INTRODUCTION
Antibodies have proved to be valuable reagents in studies of the structure, function and biosynthesis of a variety of cell surface receptors and other minor membrane proteins. Polyclonal antibodies for the insulin receptor have been obtained by immunization of rabbits with purified receptor (Jacobs & Cuatrecasas, 1981) or from human subjects with a rare syndrome in which autoantibodies for the receptor occur spontaneously (Kahn et al., 1981) . Such antibodies have contributed greatly to studies on the structure (Harrison & Itin, 1980; Jacobs et al., 1980) , function (Kasuga et al., 1982; Gazzano et al., 1983) and biosynthesis (Deutsch et al., 1983; Hedo et al., 1983) of the insulin receptor. At the functional level the value of such antibodies is limited by their polyclonal and therefore heterogeneous nature, resulting in the simultaneous recognition of multiple epitopes and a variety ofdifferent biological effects (Kahn et al., 1977; Jacobs et al., 1978) .
Many aspects of insulin action and details of receptor structure remain unclear at the molecular level. In particular, the nature of the signal generated by hormone-receptor interaction, which mediates effects on intracellular enzymes, remains to be established Czech, 1985) .Acompletedescription will require identification and characterization of the different structural and functional domains of the receptor, to complement the recently published primary sequence (Ullrich et al., 1985; Ebina et al., 1985) . This information may also clarify structural and functional relationships with receptors for other growth factors.
Monoclonal antibodies, because of their fine specificity and availability in quantity in purified form, have been especially useful in providing new insights into the structure and function of receptors for acetylcholine (Lindstrom et al., 1983; Fuchs et al., 1984) and epidermal growth factor (Schlessinger et al., 1984; Parker et al., 1984; Gill et al., 1984) . In these instances, substantial numbers of antibodies reacting with distinct sites, and with different biochemical effects, have been obtained. Monoclonal antibodies for the insulin receptor have been more elusive and very few have so far been described in detail (Roth et al., 1982; Kull et al., 1983) . We have prepared 28 monoclonal antibodies which react with at least 10 epitopes on the human insulin receptor, and here describe the initial characterization of these antibodies. Preliminary accounts of some of these findings and other properties of the antibodies have been presented elsewhere Soos et al., , 1986 .
and NSO/ 1 (NSO) were a gift from Dr. C. Milstein. Mice were from Bantin & Kingman, Hull, Humberside, U.K. IM-9 lymphocytes were obtained initially from Flow Laboratories, Irvine, Scotland.
Sheep anti-(mouse immunoglobulin) and sheep anti-(rabbit immunoglobulin) antibodies were prepared as described previously (Soos & Siddle, 1982) , and coupled to aminocellulose to obtain immunoadsorbents also as described previously (Hales & Woodhead, 1980) . InsulinSepharose was prepared by coupling bovine insulin to Sepharose 4B via a spacer arm as described by Fujita-Yamaguchi et al. (1983) .
Normal human placenta was freshly obtained at delivery. Human liver was obtained at post mortem approx. 24 h after death. Animal livers were obtained immediately after killing from a slaughterhouse.
Radioiodinations
Purified human placental insulin receptor (FujitaYamaguchi et al., 1983) was iodinated using a stoichiometric chloramine-T method (Roth, 1975) . Na'251 (0.1-0.2 mCi in 25 ,l of0.5 M-sodium phosphate, pH 7.4) was added at room temperature to receptor (1-2 jug in 100 #1 of 0.05 M-Tris/HCl, pH 7.4, containing 0.1 mM-PMSF and approx. 0.5% Triton X-100), followed by the addition, in 10 ,1 portions over 20-25 min, of 50 #1 of chloramine-T (20 ,ug/ml in 0.05 M-sodium phosphate buffer, pH 7.4). lodinated receptor was separated from free iodide and Triton micelles by applying the reaction mixture to an Ultrogel AcA-34 column (0.9 cm x 58 cm) at 4°C and eluting with 0.05 M-Tris/HCl (pH 7.4)/0.1 nM-PMSF/0.1% Triton X-100, with a flow rate of 2 ml/h. Fractions (0.5 ml) were collected and those containing receptor were pooled. Approx. 2-3% of the total radioactivity was incorporated into protein, giving a specific radioactivity of approx. 3-5,uCi/,ug.
Mono-'251-insulin with a specific radioactivity of 150-200 /tCi/,ug was prepared from highly purified bovine insulin as described by Linde et al. (1981) . Sheep anti-(rabbit immunoglobulin) and sheep anti-(mouse immunoglobulin) antibodies were affinity-purified and iodinated as described previously (Hales & Woodhead, 1980) .
Assays
Immunoprecipitation of 1251-receptor. Antibody was incubated with 1251I-receptor (2000 c.p.m.) in 100 lO of Buffer A (0.075 M-Tris/HCl, pH 7.3 at room temperature, containing 0.03 M-NaCl, 0.01 M-glucose, 0.5 mM-EDTA, 0.1 mM-PMSF and 0.1 % BSA) containing 0.05% Triton X-100 for 2 h at 20°C or 18 h at 4 'C. Sheep anti-(mouse immunoglobulin) adsorbent (0.25 mg in 50 ,u ofthe same buffer) was then added for 30 min at 20 'C or 2 h at 4 'C. Incubations were diluted with 1 m of cold, 0.1 M-sodium phosphate buffer, pH 7.4, containing 1 % BSA and 0.1 % Triton X-100, centrifuged at 2000 g for 10 min at 4 'C and the pellets washed once with the same buffer, before counting for radioactivity.
Immunoprecipitation of receptor-1251-insulin complexes. Receptor, solubilized from placental membranes with 2% (v/v) Triton X-100 (Fujita-Yamaguchi et al., 1983) , was preincubated for 18 h at 4 'C with 1261-insulin (20000 c.p.m., 100 pM) in 50 ,1 of Buffer A containing 0.05% Triton X-100. Receptor-bound 125I-insulin was determined by precipitation with poly(ethylene glycol) 6000 as previously described (Baron & Sonksen, 1982) . Sufficient receptor was used to bind 5-10% of the 1251-insulin under these conditions. Antibody (50 ,ll) was then added for a further 18 h at 4°C and antibody-bound radioactivity was determined using a sheep anti-(mouse immunoglobulin) adsorbent as described above.
Insulin binding to membranes. Placental membranes (Fujita-Yamaguchi et al., 1983) in 100 ,pl of buffer A were preincubated with 100 pA of antibody or insulin for 2 h at 4°C, before addition of 1251-insulin (20000 c.p.m., 100 pM) in 50,1 of buffer A for a further 18 h at 4 'C. Membrane-bound radioactivity was separated by filtration through 0.22 ,m cellulose acetate filters, presoaked in 0.1 M-sodium phosphate buffer (pH 7.4)/1 % BSA, followed by washing with 10 ml of the same ice-cold buffer. Sufficient membranes were used to bind 5-10% of the added radioactivity in the absence of antibody or insulin. Non-specific binding was determined by incubation with 1 /SM-insulin.
Insulin binding to IM-9 cells. 1251-insulin binding to IM-9 lymphocytes was determined as described by Roth et al. (1982) by preincubating 100 ,1 ofcells for 30 min at 15 'C with 100 #l of antibody or insulin, before addition of 50 #1 of 125I-insulin for a further 75 min at 15 'C.
Production of monoclonal antibodies
The monoclonal antibodies described were obtained from Balb/c mice following two different immunization regimes. One group (92 mice including those coded numbers 47 and 83) was given two intraperitoneal injections of IM-9 lymphocytes [(2-4) x 106 cells in saline] at 1 month intervals and then rested for 5-6 months. The second group (28 mice including those coded numbers 18 and 25) received two to five subcutaneous and footpad injections of purified receptor (0.5-2,g in Freund's adjuvant) over several months, the receptor being obtained at this time by the method of Jacobs & Cuatrecasas (1981) . Mice were test bled from the tail 10-15 days after boosting, and sera were monitored for the presence of anti-receptor antibody as described above. Six mice from each group with the highest serum antibody titres then received an intravenous boost, 4 days before fusion, with 1-2,g of purified receptor prepared now by the improved method of Fujita-Yamaguchi et al. (1983) . Spleen cells from these mice were fused with NSI (mice 25, 47, 83) or NSO (mouse 18) myeloma cells by using standard techniques (Galfre & Milstein, 1981) . The cells from each fusion were plated onto 384 wells of microtitre trays, and vigorous hybrid growth was normally obtained in all wells. Culture supernatants were screened for anti-receptor antibodies by immunoprecipitation of 125I-receptor as described above. Positive wells were detected in only five out of the 12 fusions, giving 36 persistent positive wells in all. These cells were cloned twice at limiting dilution, using spleen cell feeder layers. Cloning was successful for 28 cell lines which were then grown as ascitic tumours in mice. Antibody for characterization was partially purified from ascites fluid by precipitation with 40%0 saturated (v/v) (NH4)2SO4 followed by reconstitution in PBS to the original ascites volume.
Isotyping of antibodies
Chain class was determined in the 1251-receptor binding assay by using immunoadsorbents containing rabbit antibodies specific for mouse immunoglobulin subclasses, prepared as described by Soos & Siddle (1982) . Results were confirmed in a dot immunobinding assay (Beyer, 1984) .
Tissue and species specificity of antibodies Crude microsomal membranes and wheatgerm agglutinin-Sepharose purified receptors were prepared from human tissues and animal livers as described by Fujita-Yamaguchi et al. (1983) for placenta. The specificity of antibodies was determined by testing their ability to inhibit 1251-insulin binding to membranes or by their ability to immunoprecipitate receptor-125I-insulin complexes as described above.
Investigation of antigenic determinants on the insulin receptor
The relationship between the binding sites for different antibodies was investigated by competition studies, in which the ability of soluble antibody to inhibit binding of 125I-antigen to an antibody on solid phase was tested. Antibodies were bound to solid phase by incubating 10 mg of sheep anti-(mouse immunoglobulin) adsorbent with anti-receptor antibody (1:8 dilution) in 2.5 ml of 0.05 M-Tris/HCl (pH 7.4)/0.1 % Triton X-100/0.1 mm-PMSF for 18 h at 4°C, followed by extensive washing with the same buffer. 125I-receptor (5000 c.p.m.) was preincubated with soluble antibody (2 ,l) and nonimmune mouse serum (3%, v/v) in 100l 1 of 0.05 MTris/HCl (pH 7.4)/0.1% Triton X-100 for 18 h at 4°C, before addition of 0.25 mg of adsorbent containing mouse anti-receptor antibody (100 ,1) for 30 min at 20 'C. Incubations were then terminated by the addition of 2 ml of cold 0.1 M-sodium phosphate (pH 7.4)/0.1 % BSA/0.1% Triton X-100, and radioactivity bound to solid phase anti-receptor antibody was determined after centrifugation at 2000 g for 10 min at 4 'C.
Immunoblotting
Purified placental insulin receptor (approx. 10-20 jug) was reduced in sample buffer containing 50 mMdithiothreitol, and electrophoresed across the whole width (15 cm) of a 7.5% polyacrylamide gel (Laemmli, 1970) . The gel was blotted onto 0.2,m nitrocellulose paper as described previously (Burnette, 1981) and the paper was then incubated in PBS containing 2% (w/v) Marvel dried milk for 1 h at 20 'C. Strips of this paper were incubated with antibody at a dilution relative to ascites fluid of 1: 10, in 3 ml ofPBS containing 2% Marvel and 0.5% Tween 20, for 2 h at 20 'C. The strips were washed in PBS/2% Marvel/0.5% Tween, PBS/0.5% Tween, PBS/0.05% SDS/0.5% Triton X-100/0.5% sodium deoxycholate/2.5 mM EDTA, and finally PBS/0.05% Tween. They were then incubated with horseradish peroxidase-conjugated goat anti-(mouse immunoglobulin) antibody at a dilution of 1:2000 in 3 ml of PBS/2% Marvel/0.5% Tween for 2 h at 20 'C. Washing was carried out as previously and then with PBS alone, before addition of peroxidase substrate consisting of diaminobenzidine (0.2 mg/ml), CoCl2 (0.3 mg/ml) and H202 (0.06 mg/ml) in PBS.
RESULTS

Production and preliminary characterization of antibodies
Only 12 mice, out of 120 immunized, developed a serum titre of anti-receptor antibody which was considered sufficient to justify a fusion (at least half-maximal response in one or more screening assays with 1: 200 dilution of serum). Most of the monoclonal antibodies obtained came from two animals (numbers 18 and 83) which had easily the highest serum titres. There were also important qualitative differences between the serum antibodies in different animals. Ofthose immunized initially with IM-9 cells, mouse 47 produced predominantly antibody which inhibited insulin binding and mouse 83 predominantly non-inhibitory antibody, while other mice had both types ofantibody. It was not possible to assess the serum antibody in this way for mice immunized with affinity-purified receptor (including numbers 18 and 25) because of the presence in these sera of antiinsulin antibodies.
Twenty-eight different monoclonal antibodies were obtained, from four separate fusions (Table 1) . These were detected initially in the screening assay with 1251-receptor, and were then studied further to determine their effect on 1251-insulin binding to IM-9 lymphocytes and their ability to precipitate receptor-bound 1251-insulin (Fig. 1) . The antibodies fell into four major groups on this basis. All three antibodies from mouse 47 strongly inhibited 1251-insulin binding, and did not bind the receptor-1251-insulin complex. A large group of 15 antibodies from mouse 18 had relatively little effect in the binding inhibition assay but reacted well with the receptor-1251-insulin complex. Three antibodies from mice 25 and 83 reacted well in both assays. Seven antibodies from mice 18 and 83 reproducibly increased the binding of 251-insulin to IM-9 cells, in addition to binding the receptor-1251-insulin complex.
The antibodies 25-49,47-9,47-46 and 83-14 which most strongly inhibited 125I-insulin binding to IM-9 cells were investigated further to determine the concentrationdependence of this effect. Half-maximal inhibition was obtained at final antibody dilutions of 1: 25000-1: 75000 relative to ascites fluid, or approx. 0.2-1 nm assuming a typical concentration of 2-5 mg/ml in neat tumour fluid. The antibodies were therefore approximately equipotent with insulin itself, which was half-maximally effective at 0.5 nm under the same conditions. Most antibodies were of IgG1 subclass, although some IgG2., IgG2b and IgM antibodies were also obtained (Table 1) . Tissue specificity The reaction of antibodies with receptor from human placenta, human liver and IM-9 cells was studied in 1251-insulin binding-inhibition or co-precipitation assays as appropriate. Typical results are shown in Figs. 2 and 3. The antibodies reacted well with all tissues although there were minor reproducible differences. Thus, the inhibitory antibodies were consistently less effective with liver than with placental or IM-9 membranes. This was evident both in a rightward shift and shallower slope of the dose-response curve, and in failure completely to inhibit specific binding of 1251-insulin at the highest concentration tested (Fig. 2) . Some, but not all, of the non-inhibitory antibodies similarly were somewhat less effective in precipitating 1251-insulin bound to solubilized Vol. 235 $ Reactivity of antibodies (at 1:100-1:1000 dilution) in the assay of 1251-insulin-receptor co-precipitation is classified as immunoprecipitation of all (+) or none (-) of poly(ethylene glycol)-precipitable radioactivity.
§ Cross reaction is defined from relative antibody concentrations reacting with rabbit or bovine liver receptorcompared with human liver. Where possible titres were compared at half-maximal binding levels, the relative cross-reactions being 50-100% (+ +), 1-10% (+), 0.1-1 % (±) or insignificant reaction (-) . Results in parentheses indicate titration curves which were not parallel to those with human liver.
11 The pattern of cross reaction is indicated by the Figure number which it most closely resembles.
Subunit reactivity (a or ,i) in immunoblots with purified receptor (Fig. 7) is indicated. Lack of reaction is denoted by 0, and gaps indicate antibodies which were not tested. ** Antibodies were grouped into epitopes, on the basis of differences in species specificity and/or binding competition (Fig. 6) . The numbered epitopes which were clearly distinct (1-10) were in some cases subdivided (A-D) where antibodies showed relatively minor differences but also significant similarities in properties.
liver rather than placental receptors, both in terms of concentration dependence and maximal effect (Fig. 3) . Species specificity Species specificity was investigated by using human, rabbit, bovine, porcine, sheep and rat liver membranes in both the 1251-insulin binding-inhibition and co-precipitation assays. None of the antibodies reacted with rat liver receptors (results not shown). All antibodies reacted very similarly with bovine, porcine and sheep receptors, so that for simplicity only results with bovine liver are shown in each case.
The antibodies which inhibited insulin binding displayed three main patterns of cross-reaction. One group, typified by antibody 47-9, reacted equally with human and bovine receptors and rather less well with rabbit, while antibody 25-49 showed no reaction with bovine receptors (Fig. 4) . Antibody 83-14 on the other hand reacted with bovine but not rabbit receptors in the inhibition assay (result not shown), as in the coprecipitation assay (Fig. 5) .
The antibodies studied in the co-precipitation assay displayed complex patterns of cross-reaction (Fig. 5) 
Analysis of epitopes
The effects of antibodies on insulin binding and the various patterns of species cross-reaction in themselves indicated recognition of several distinct sites on the receptor. These differences in epitope were further analysed by competitive binding experiments and by immunoblotting.
Competition studies were carried out by testing the effect of preincubation of 125I-receptor with one antibody in solution on subsequent binding to a second immobilized antibody (Fig. 6) . The observed inhibition was not always all or none as might be predicted on simple models of steric competition. Moreover, in a few cases, mutual reciprocal inhibition was not observed. For instance, soluble antibody 83-14 blocked binding to immobilized antibody 47-9, but not vice versa, and soluble antibody 83-7 blocked binding to immobilized antibody 18-38, but not vice versa. Nevertheless, similarities and differences in overall pattern enabled the antibodies to be placed in a variety of distinct epitope groups (Table 1) .
Attempts were made to localise the epitopes to either the ax or , subunit of the receptor by means of immunoblotting, after separation of the subunits on polyacrylamide gels under reducing conditions (Fig. 7) . A polyclonal rabbit anti-receptor serum reacted strongly with both subunits. The reactions of the monoclonal antibodies were weaker but in several cases were unequivocally with one or other of the subunits (Table  1) . Some antibodies, such as 83-7, 83-15 and 83-16, which appeared similar in reactivity by various criteria, showed no detectable reaction in immunoblotting experiments with reduced receptor.
Binding of monoclonal antibodies to intact IP-9 cells at 15°C was investigated in an indirect assay using 1251I-rabbit anti-(mouse immunoglobulin) antibody. Conditions for saturation of available binding sites for both first and second antibodies are difficult to achieve without also introducing high levels of' non-specific' binding, and the extent of binding of labelled antibody may also depend on monoclonal antibody subclass. Such an assay does not therefore easily provide a quantitative measure of antigen concentration. Nevertheless, all antibodies showed significant binding to IM-9 cells, within a 2.5-fold range ofradiolabelled second antibody bound (results not shown), indicating that all epitopes were accessible at the cell surface and present in broadly similar numbers.
DISCUSSION
The aim of the work described in this paper was to obtain antibodies reacting with multiple sites on the insulin receptor, for use as probes of receptor structure and function; 28 antibodies, recognizing at least 10 epitopes, were obtained from four fusions. Different animals yielded distinct groups of antibodies, indicating considerable individual variation in the epitopes recognized. It is possible that the form of immunogen used, either IM-9 cells or purified receptor, has some influence on the dominant epitopes expressed. The screening assay employed may also introduce bias in the type of antibody obtained, either inhibitory or non-inhibitory with respect to insulin binding (Roth et al., 1982; Kull et al., 1983 ), although we deliberately used an assay which detected antibodies of both types. Recently, described a large number ofmonoclonal antibodies Vol. 235 for epitopes on the intracellular protein kinase domain of the insulin receptor, and concluded that this represents the major antigenic region ofthe receptor. However, most of these antibodies came from a single animal. All our antibodies in contrast appeared to react with extracellular domains as shown by binding to intact IM-9 cells. Our failure to obtain any antibodies similar to those of may have resulted from the use in screening assays of receptor which was partly proteolysed (Fujita-Yamaguchi, 1984) and therefore probably deficient in protein kinase domain. Several antibodies were identified which inhibited insulin binding, involving at least three distinct epitopes, and all these antibodies were shown to react with the a subunit of the receptor on immunoblots (Table 1) . None of the antibodies reacting with fl-subunit inhibited binding, and some a-subunit reactive antibodies (e.g. 18-26) were also non-inhibitory. These observations are consistent with the demonstration by photoaffinitylabelling and cross-linking experiments (Pilch & Czech, 1979; Wisher et al., 1980) that the binding site for insulin is predominantly associated with the a-subunit. Some antibodies (e.g. 83-14 and 25-49) were effective both at inhibiting 125I-insulin Siddle, unpublished work) . This suggests that these antibodies induce or stabilize conformational changes similar to those responsible for negative co-operativity of insulin binding (De Meyts et al., 1976) . Some other antibodies in contrast enhanced the binding of 1251-insulin to IM-9 cells and solubilized receptor (Fig. 1) , as previously observed with a polyclonal antiserum (Grunfeld, 1984) . These findings indicate that there are multiple conformational states of the receptor which may be favoured by the binding of different antibodies. Conformational flexibility must also be invoked to account for insulin-induced transmembrane activation of receptor kinase activity (Kasuga et al., 1982) and changes in sensitivity of the receptor to proteolysis (Pilch & Czech, 1980) . The phenomenon of negative co-operativity (De Meyts et al., 1976) (Czech, 1985) it is possible to envisage a disposition of epitopes which would lead to non-reciprocal inhibition on the basis of steric hindrance alone. Receptor heterogeneity arising from partial proteolysis (Fujita-Yamaguchi, 1984) (Roth et al., 1983; Kull et al., 1983) remains to be established. In the case of epidermal growth factor receptors some monoclonal antibodies reacted with carbohydrate determinants also found on other cell surface molecules (Parker et al., 1984) . However, several lines of evidence point to a high degree of specificity in the antibodies we have described. One antibody (18-42) has been used in the immunoaffinity purification of placental insulin receptor (O'Brien et al., 1986) and another (83-14) in the specific immunoprecipitation of receptor from biosynthetically labelled lymphocytes (J. Bellatin, E. S. Lennox & K. Siddle, unpublished work). In both cases, analysis of the immunoreactive material by SDS/polyacrylamide-gel electrophoresis revealed the a and , subunits of receptor as the major polypeptides. The binding assays we have carried out also showed that all antibodies bound to intact IM-9 cells to a similar extent irrespective of individual epitopes, suggesting that the major reaction is with the same macromolecule. However, binding studies by Scatchard analysis with monovalent antibody fragments will be necessary to quantify the precise number of sites for each antibody together with the respective binding affinities. In terms of ability to inhibit binding of 1251-insulin, antibodies 25-49 and 47-9 appeared to be of similar potency to insulin itself. Some antibodies however were clearly of low avidity and it was one of these which proved useful in the immunoaffinity purification of insulin receptors (O'Brien et al., 1986) .
Our findings to date provide no clear support for the existence of structural heterogeneity of insulin receptors within or between the tissues studied (Figs. 2 and 3 ), although they do not rule out the possibility of different affinity states in situ within a given population of receptors. Some small differences were observed in the reactivity ofantibodies with receptor from liver compared with placenta or IM-9 cells. The possibility exists that these result from post-mortem changes in the liver before processing rather than inherent tissue differences, and further work is required to investigate this. We saw no difference in reactivity of any of our antibodies with IM-9 cells compared to placenta, although a previous report described a monoclonal antibody which was somewhat more effective at inhibiting insulin binding to IM-9 cells than to placenta or adipocytes (Roth et al., 1982) . This antibody also shows discrimination in the case of receptors from human brain, with which it reacts weakly relative to placenta . It is possible therefore that there are subtle differences between receptors in different tissues, perhaps reflecting posttranslational modifications.
The present large group of antibodies reveal a considerable degree of species divergence in receptor structure even in regions close to the insulin binding site (Figs. 4 and 5 ). This contrasts with the previously assumed conservation of structure during evolution, based on relative binding affinity of different insulins (Kemmler et al., 1978) . Substantial homology between species was also indicated by the cross-reaction of human autoantibodies with rat receptor (Kahn et al., 1977) and of rabbit antisera to rat receptor with human tissues (Kull et al., 1982) . None of our monoclonal antibodies for the human receptor reacted with rat receptor, as reported also for other monoclonal antibodies (Roth et al., 1982; Kull et al., 1983) . This possibly reflects a selection against any common epitopes which (assuming rat and mouse . Epitope analysis by immunoblotting Protein blots of purified receptor, which had been fractionated by SDS/polyacrylamide-gel electrophoresis, were probed with monoclonal antibodies ( 1: 10 dilution relative to ascites) or a rabbit polyclonal antiserum (1: 100 dilution of serum), as described in the Experimental section. Mobilities of standard molecular mass markers are indicated at the side in kDa. Antibody codes are indicated above each strip.
receptors to be very similar) might not be recognized as foreign in rodents. On the other hand, mouse monoclonal antibodies for the intracellular protein kinase domain of human insulin receptor do cross-react with rat receptor , indicating that this structure at least is highly conserved and yet still immunogenic under suitable conditions. Preliminary studies indicate that several of our antibodies exert insulin-like effects on the metabolism of isolated human adipocytes ) and it will be interesting to characterize the binding sites and biochemical effects of these antibodies more fully in relation to current theories of the mechanism of insulin action.
